About RethinkTHC

Who We Are

RethinkTHC is an independent cannabis science education platform. We are not anti-cannabis. We are not pro-cannabis. We are pro-evidence.

Founded in 2026, RethinkTHC exists because the public conversation about cannabis is broken. The cannabis industry tells you it is harmless. The abstinence lobby tells you it will ruin your life. Neither is giving you the full picture. We exist to fill that gap with peer-reviewed evidence, transparent methodology, and editorial independence.

RethinkTHC is not affiliated with any cannabis company, dispensary, advocacy group, government agency, or trade organization. We are an independent editorial operation with a single mission: give people the science they need to make informed decisions.

Our Expertise

RethinkTHC content is produced by the RethinkTHC Research Team — a dedicated editorial operation focused exclusively on translating cannabis science into accessible, accurate public health education. Our editorial process involves systematic literature review across four core domains:

• Neuroscience — endocannabinoid system function, CB1/CB2 receptor dynamics, dopamine pathway modulation, prefrontal cortex and amygdala interactions
• Pharmacology — THC and CBD pharmacokinetics, drug interaction profiles, tolerance and sensitization mechanisms, withdrawal pharmacology
• Psychiatry — cannabis use disorder, comorbid mental health conditions, psychosis risk, anxiety and depression research, self-medication patterns
• Public health — harm reduction frameworks, population-level trends, legalization outcomes, impaired driving research, vulnerable population considerations

Our systematic literature review draws from journals including JAMA, JAMA Network Open, JAMA Psychiatry, The Lancet, The Lancet Psychiatry, New England Journal of Medicine, Neuropsychopharmacology, Molecular Psychiatry, Biological Psychiatry, American Journal of Psychiatry, PLOS ONE, Sleep, and Current Psychiatry Reports. We also reference clinical guidelines from the DSM-5, SAMHSA, ACOG, NIDA, and the WHO.

Our Database

RethinkTHC maintains one of the most comprehensive publicly accessible cannabis research databases available. As of March 2026, our database includes:

Every study in our database is tagged, rated for evidence strength, classified by study type, and linked to relevant articles. Our research database is freely accessible and searchable by topic, evidence strength, and study type. Read more about our evidence methodology.

Editorial Independence

Our credibility depends on our independence. We guard it carefully.

• No cannabis industry funding. We do not accept funding, grants, sponsorships, or financial support of any kind from cannabis companies, dispensaries, or cannabis-adjacent businesses.
• No cannabis advertising. We do not display advertisements from cannabis companies, CBD brands, or dispensaries. We do not accept sponsored content.
• No affiliate relationships. We do not earn commissions or referral fees from any cannabis product, dispensary, or related service. We have no affiliate links.
• Evidence-driven content. Every editorial decision is driven by the research. We cover both the potential benefits and the documented risks of cannabis use with equal rigor and transparency.

Our Methodology

Every article published on RethinkTHC follows a multi-stage editorial pipeline designed to meet the highest standards of health science communication:

1. Research and source identification. Systematic literature review across PubMed, Google Scholar, and journal databases. Relevant studies pulled from our verified citation library of 6,500+ sources.
2. Drafting with inline citations. Articles composed with every factual claim tied to a named, verifiable source during the writing process — not added after the fact.
3. Scientific accuracy review. All claims cross-referenced against original source studies. Numbers, percentages, sample sizes, and methodology descriptions verified for accuracy.
4. Preflight verification. Automated checks confirm formatting consistency, metadata completeness, structural integrity, and schema validation.
5. Publication with version tracking. Every article published with both datePublished and dateModified timestamps. All substantive changes reflected in modification dates.

Evidence strength is rated transparently using a three-tier system: well-established, moderate, and preliminary. Study limitations are always noted. When the evidence is mixed or uncertain, we say so. Read the full details in our evidence methodology and editorial policy.

What Makes Us Different

We are neither pro-cannabis nor anti-cannabis. We are pro-evidence.

• We do not cherry-pick studies that support a particular viewpoint. When a finding supports cannabis benefits, we report it. When a finding identifies risks, we report that too.
• We do not use phrases like “studies show” without naming the specific study. Every claim names author(s), year, and journal.
• We distinguish between well-established findings and preliminary research. We do not present single pilot studies as settled science.
• We report honest uncertainty. When we do not know something, we say “the research has not established this” rather than speculating.
• Our research database is freely accessible. You can verify every claim we make by looking up the named study yourself.

Corrections and Accountability

We welcome corrections. If you find an error in any article or study summary — a misquoted statistic, an outdated finding, a broken source reference, or any other inaccuracy — we want to know about it.

• Email corrections to corrections@rethinkthc.com
• We review all submissions and respond within 7 days
• All corrections are logged with transparent versioning
• Every article displays both datePublished and dateModified
• We do not silently alter published content — substantive changes are always reflected in the modification date

What We Cover

Our 365 articles and 20 research pillars span the full spectrum of cannabis science:

• Cannabis withdrawal and recovery — timeline, symptoms, coping strategies, and the neuroscience of CB1 receptor recovery
• Medical cannabis research — what the evidence actually supports for pain, epilepsy, nausea, anxiety, and other conditions
• Harm reduction — lower-risk use guidelines, consumption method safety profiles, tolerance management, and product quality
• Mental health — the anxiety paradox, self-medication patterns, cannabis-induced psychosis risk, and depression research
• Neuroscience — how THC interacts with the endocannabinoid system, dopamine pathways, prefrontal cortex, and amygdala
• Drug interactions — CYP450 enzyme inhibition, medication interactions, and combination risk profiles
• Specific populations — teenagers, pregnant women, seniors, athletes, healthcare workers, and people of faith

Get in Touch

Have a question, correction, or topic suggestion? We would love to hear from you.

• General inquiries: hello@rethinkthc.com
• Corrections and error reports: corrections@rethinkthc.com

Medical Disclaimer

RethinkTHC provides educational content only. Nothing on this site constitutes medical advice, diagnosis, or treatment. We are not a healthcare provider and do not provide clinical services. Always consult a qualified healthcare provider before making decisions about cannabis use, particularly if you have a medical condition or take prescription medications. Read our full medical disclaimer.